112086-52-9

Basic information

• Product Name: BENZYL-(3-IMIDAZOL-1-YL-PROPYL)-AMINE
• Synonyms: BENZYL-(3-IMIDAZOL-1-YL-PROPYL)-AMINE;N-benzyl-3-imidazol-1-ylpropan-1-amine
• CAS NO: 112086-52-9
• Molecular Formula: C₁₃H₁₇N₃
• Molecular Weight: 215.29
• Mol File: 112086-52-9.mol

Chemical Properties

• Boiling Point: 399.3±25.0 °C(Predicted)
• Appearance: /
• Density: 1.04±0.1 g/cm3(Predicted)
• PKA: 8.97±0.19(Predicted)
• CAS DataBase Reference: BENZYL-(3-IMIDAZOL-1-YL-PROPYL)-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: BENZYL-(3-IMIDAZOL-1-YL-PROPYL)-AMINE(112086-52-9)
• EPA Substance Registry System: BENZYL-(3-IMIDAZOL-1-YL-PROPYL)-AMINE(112086-52-9)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 112086-52-9(Hazardous Substances Data)

Upstream product

• 5036-48-6 3-(1H-imidazol-1-yl)propan-1-amine 
• 100-52-7 benzaldehyde 
• 820220-10-8 N-benzylidene-3-(1H-imidazo-1-lyl)-1-propaneamine 

Downstream Products

• 944469-31-2 C₂₃H₃₃N₅O₃ 
• 279236-97-4 2(R)-[[[3-(1H-imidazol-1-yl)propyl](phenylmethyl)amino]carbonyl]piperazine 

Relevant articles and documents

Discovery of Novel Acetamide-Based Heme Oxygenase-1 Inhibitors with PotentIn VitroAntiproliferative Activity

Heme oxygenase-1 (HO-1) promotes heme catabolism exercising cytoprotective roles in normal and cancer cells. Herein, we report the design, synthesis, molecular modeling, and biological evaluation of novel HO-1 inhibitors. Specifically, an amide linker in the central spacer and an imidazole were fixed, and the hydrophobic moiety required by the pharmacophore was largely modified. In many tumors, overexpression of HO-1 correlates with poor prognosis and chemoresistance, suggesting the inhibition of HO-1 as a possible antitumor strategy. Accordingly, compounds7iand7l-pemerged for their potency against HO-1 and were investigated for their anticancer activity against prostate (DU145), lung (A549), and glioblastoma (U87MG, A172) cancer cells. The selected compounds showed the best activity toward U87MG cells. Compound7lwas further investigated for its in-cell enzymatic HO-1 activity, expression levels, and effects on cell invasion and vascular endothelial growth factor (VEGF) extracellular release. The obtained data suggest that7lcan reduce cell invasivity acting through modulation of HO-1 expression.

Scalable methodologies for the synthesis of novel unsymmetrically substituted secondary amines

Fast, easy, and scalable methodologies for the synthesis of unsymmetrically substituted secondary amines containing naphthalene, indole, pyridine and imidazole moieties through reductive amination were explored. The investigated operating procedures were

PIPERAZINE DERIVATIVES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS

Disclosed are compounds of the formula: wherein R13 represents an imidazole ring; R14 represents a carbamate, urea, amide or sulfonamide group, and the remaining substituents are as defined herein. Also disclosed is a method of treating cancer and a method of inhibiting farnesyl protein transferase using the disclosed compounds.

NOVEL INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

Novel compounds and pharmaceutical compositions are disclosed which are inhibitors of the enzyme, farnesyl-protein transferase. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering the novel aminooxyamide compound to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human.

Anthranilamides and methods of their use

The present invention is related to anthranilamides of formula I, in which R(1) to R(7) have the meanings indicated herein, a process for their preparation, their use as medicaments, and pharmaceutical preparations containing them. The compounds act on the Kv1.5 potassium channel and inhibit a potassium current which is referred to as the ultra-rapidly activating delayed rectifier in the atrium of the human heart. The compounds are therefore suitable for use as novel antiarrhythmic agents for the treatment and prophylaxis of atrial arrhythmias (e.g., atrial fibrillation (AF) or atrial flutter).